JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation.

J Neuroinflammation January 22, 2026 DOI: 10.1186/s12974-026-03699-1 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed
Topics	Depression Esketamine

Abstract

Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation.